The US Food and Drug Administration (FDA) has approved the type 2 anti-CD20 monoclonal antibody obinutuzumab (Gazyva) for patients with follicular lymphoma, a common type of non-Hodgkin lymphoma.
Hematologic Cancer Targets
Laboratory studies of mice and human cells found that a protein called Metastasis suppressor 1 (Mtss1) is downregulated in hematopoietic and progenitor cells when chronic myeloid leukemia is present. Mtss1 levels are restored when complete remission is achieved, suggesting the pathway might represent a new therapeutic target.
The FDA granted approval to ofatumumab for the treatment of patients with recurrent or progressive chronic lymphocytic leukemia who are in complete or partial remission after two or more lines of prior therapy.
The FDA recently expanded the drug label for carfilzomib (Kyprolis), which is now approved in combination with dexamethasone or with lenalidomide plus dexamethasone for patients with relapsed or refractory disease who have received one to three lines of therapy.
A laboratory study found that the Hhex protein is overexpressed in acute myeloid leukemia cells and is necessary for their propagation but not for normal myelopoiesis.
On November 30, 2015, the US Food and Drug Administration (FDA) approved elotuzumab (Empliciti, Bristol-Myers Squibb) as a second-line treatment for multiple myeloma, in combination with two other agents.
The FDA approved the proteasome inhibitor ixazomib, in combination with lenalidomide and dexamethasone, to be used as a second-line treatment in multiple myeloma.
On November 16, 2015, the US Food and Drug Administration (FDA) approved daratumumab (Darzalex) to treat patients with multiple myeloma who have received at least three prior treatments.
The FDA recently granted priority review status to ixazomib (Takeda) for the treatment of relapsed or refractory multiple myeloma.
Treatment with a short course of vemurafenib was effective and rapid in patients with relapsed or refractory hairy-cell leukemia, resulting in overall response rates of over 95%.